Quarterly report · Q3

Period2023-04-01 → 2023-12-31
Filed2024-02-09
StandardIFRS
ConsolidatedYes
Data checks16 of 16 passed
Key figures · 61
MetricValuePeriodScopeSource row
Revenue¥683.0bn2023-04-01 → 2023-12-31Cons.Revenue IFRS
Revenue¥239.1bn2023-10-01 → 2023-12-31dCons.Revenue IFRS
Revenue¥820.2bn2022-04-01 → 2023-03-31Cons.Revenue IFRS (5-year summary)
Revenue¥618.0bn2022-04-01 → 2022-12-31Cons.Revenue IFRS
Revenue¥214.7bn2022-10-01 → 2022-12-31dCons.Revenue IFRS
Operating income¥105.5bn2023-04-01 → 2023-12-31Cons.Operating profit loss IFRS
Operating income¥39.0bn2023-10-01 → 2023-12-31dCons.Operating profit loss IFRS
Operating income¥93.5bn2022-04-01 → 2022-12-31Cons.Operating profit loss IFRS
Operating income¥37.5bn2022-10-01 → 2022-12-31dCons.Operating profit loss IFRS
Profit before tax¥105.7bn2023-04-01 → 2023-12-31Cons.Profit loss before tax IFRS
Profit before tax¥39.3bn2023-10-01 → 2023-12-31dCons.Profit loss before tax IFRS
Profit before tax¥116.1bn2022-04-01 → 2023-03-31Cons.Profit loss before tax IFRS (5-year summary)
Profit before tax¥92.1bn2022-04-01 → 2022-12-31Cons.Profit loss before tax IFRS
Profit before tax¥37.5bn2022-10-01 → 2022-12-31dCons.Profit loss before tax IFRS
Net income (owners)¥79.9bn2023-04-01 → 2023-12-31Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥29.8bn2023-10-01 → 2023-12-31dCons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥89.3bn2022-04-01 → 2023-03-31Cons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income (owners)¥70.2bn2022-04-01 → 2022-12-31Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥29.9bn2022-10-01 → 2022-12-31dCons.Profit loss attributable to owners of parent IFRS
Net income¥79.9bn2023-04-01 → 2023-12-31Cons.Profit loss IFRS
Net income¥29.8bn2023-10-01 → 2023-12-31dCons.Profit loss IFRS
Net income¥70.2bn2022-04-01 → 2022-12-31Cons.Profit loss IFRS
Net income¥29.9bn2022-10-01 → 2022-12-31dCons.Profit loss IFRS
Total assets¥1.69Tat 2023-12-31Cons.Assets IFRS
Total assets¥1.60Tat 2023-03-31Cons.Assets IFRS
Total assets¥1.54Tat 2022-12-31Cons.Total assets IFRS (5-year summary)
Total liabilities¥475.7bnat 2023-12-31Cons.Liabilities IFRS
Total liabilities¥491.2bnat 2023-03-31Cons.Liabilities IFRS
Net assets / equity¥1.22Tat 2023-12-31Cons.Equity IFRS
Net assets / equity¥1.11Tat 2023-03-31Cons.Equity IFRS
Net assets / equity¥1.07Tat 2022-12-31Cons.Equity IFRS
Net assets / equity¥1.01Tat 2022-03-31dCons.Equity IFRS
Equity (owners)¥1.22Tat 2023-12-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥1.11Tat 2023-03-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥1.07Tat 2022-12-31Cons.Equity attributable to owners of parent IFRS (5-year summary)
Cash & equivalents¥163.6bnat 2023-12-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥187.3bnat 2023-03-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥162.4bnat 2022-12-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥205.3bnat 2022-03-31dCons.Cash and cash equivalents IFRS
Operating cash flow¥91.2bn2023-04-01 → 2023-12-31Cons.Net cash provided by used in operating activities IFRS
Operating cash flow¥117.5bn2022-04-01 → 2023-03-31Cons.Cash flows from used in operating activities IFRS (5-year summary)
Operating cash flow¥74.9bn2022-04-01 → 2022-12-31Cons.Net cash provided by used in operating activities IFRS
Investing cash flow−¥53.1bn2023-04-01 → 2023-12-31Cons.Net cash provided by used in investing activities IFRS
Investing cash flow−¥59.1bn2022-04-01 → 2023-03-31Cons.Cash flows from used in investing activities IFRS (5-year summary)
Investing cash flow−¥41.9bn2022-04-01 → 2022-12-31Cons.Net cash provided by used in investing activities IFRS
Financing cash flow−¥68.7bn2023-04-01 → 2023-12-31Cons.Net cash provided by used in financing activities IFRS
Financing cash flow−¥86.6bn2022-04-01 → 2023-03-31Cons.Cash flows from used in financing activities IFRS (5-year summary)
Financing cash flow−¥84.5bn2022-04-01 → 2022-12-31Cons.Net cash provided by used in financing activities IFRS
EPS (basic)¥107.332023-04-01 → 2023-12-31Cons.Basic earnings loss per share IFRS
EPS (basic)¥40.062023-10-01 → 2023-12-31dCons.Basic earnings loss per share IFRS
EPS (basic)¥1192022-04-01 → 2023-03-31Cons.Basic earnings loss per share IFRS (5-year summary)
EPS (basic)¥93.252022-04-01 → 2022-12-31Cons.Basic earnings loss per share IFRS
EPS (basic)¥39.972022-10-01 → 2022-12-31dCons.Basic earnings loss per share IFRS
EPS (diluted)¥107.292023-04-01 → 2023-12-31Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥40.052023-10-01 → 2023-12-31dCons.Diluted earnings loss per share IFRS
EPS (diluted)¥118.952022-04-01 → 2023-03-31Cons.Diluted earnings loss per share IFRS (5-year summary)
EPS (diluted)¥93.212022-04-01 → 2022-12-31Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥39.962022-10-01 → 2022-12-31dCons.Diluted earnings loss per share IFRS
Equity ratio71.9%at 2023-12-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio69.3%at 2023-03-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio69.6%at 2022-12-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 20
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue external2023-04-01 → 2023-12-31¥172m
Reconciling Itemsreconcilingsegment profit2023-04-01 → 2023-12-31−¥2.1bn
jpcrp040300-q3r_E01630-000Blood And Cell Technologies Companyreportable segmentrevenue external2023-04-01 → 2023-12-31¥127.8bn
jpcrp040300-q3r_E01630-000Blood And Cell Technologies Companyreportable segmentsegment profit2023-04-01 → 2023-12-31¥13.9bn
jpcrp040300-q3r_E01630-000Cardiac And Vascular Companyreportable segmentrevenue external2023-04-01 → 2023-12-31¥407.7bn
jpcrp040300-q3r_E01630-000Cardiac And Vascular Companyreportable segmentsegment profit2023-04-01 → 2023-12-31¥92.0bn
jpcrp040300-q3r_E01630-000Medical Care Solutions Companyreportable segmentrevenue external2023-04-01 → 2023-12-31¥147.3bn
jpcrp040300-q3r_E01630-000Medical Care Solutions Companyreportable segmentsegment profit2023-04-01 → 2023-12-31¥16.0bn
—segment totalrevenue external2023-04-01 → 2023-12-31¥682.8bn
—segment totalsegment profit2023-04-01 → 2023-12-31¥121.9bn
Reconciling Itemsreconcilingrevenue external2022-04-01 → 2022-12-31¥186m
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-12-31¥479m
jpcrp040300-q3r_E01630-000Blood And Cell Technologies Companyreportable segmentrevenue external2022-04-01 → 2022-12-31¥113.4bn
jpcrp040300-q3r_E01630-000Blood And Cell Technologies Companyreportable segmentsegment profit2022-04-01 → 2022-12-31¥12.9bn
jpcrp040300-q3r_E01630-000Cardiac And Vascular Companyreportable segmentrevenue external2022-04-01 → 2022-12-31¥358.9bn
jpcrp040300-q3r_E01630-000Cardiac And Vascular Companyreportable segmentsegment profit2022-04-01 → 2022-12-31¥83.6bn
jpcrp040300-q3r_E01630-000Medical Care Solutions Companyreportable segmentrevenue external2022-04-01 → 2022-12-31¥145.5bn
jpcrp040300-q3r_E01630-000Medical Care Solutions Companyreportable segmentsegment profit2022-04-01 → 2022-12-31¥12.6bn
—segment totalrevenue external2022-04-01 → 2022-12-31¥617.8bn
—segment totalsegment profit2022-04-01 → 2022-12-31¥109.1bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 653
ItemContextValueUnit
Finance costs IFRSCurrentQuarterDuration799000000JPY
Share of profit loss of investments accounted for using equity method IFRSPrior1QuarterDuration440000000JPY
Share of profit loss of investments accounted for using equity method IFRSCurrentQuarterDuration-74000000JPY
Profit loss before tax IFRSPrior1QuarterDuration37475000000JPY
Profit loss before tax IFRSCurrentQuarterDuration39315000000JPY
Income tax expense IFRSPrior1QuarterDuration7616000000JPY
Income tax expense IFRSCurrentQuarterDuration9510000000JPY
Profit loss IFRSPrior1QuarterDuration29859000000JPY
Profit loss IFRSCurrentQuarterDuration29805000000JPY
Profit loss attributable to owners of parent IFRSPrior1QuarterDuration29859000000JPY
Profit loss attributable to owners of parent IFRSCurrentQuarterDuration29805000000JPY
Profit loss IFRSPrior1QuarterDuration29859000000JPY
Profit loss IFRSCurrentQuarterDuration29805000000JPY
Basic earnings loss per share IFRSPrior1QuarterDuration39.97
Basic earnings loss per share IFRSCurrentQuarterDuration40.06
Diluted earnings loss per share IFRSPrior1QuarterDuration39.96
Diluted earnings loss per share IFRSCurrentQuarterDuration40.05
Profit loss IFRSPrior1YTDDuration70180000000JPY
Profit loss IFRSCurrentYTDDuration79897000000JPY
Net change in fair value of equity instruments designated as measured at fair value through other comprehensive income net of tax items that will not be reclassified to profit or loss oci IFRSPrior1YTDDuration1982000000JPY
Net change in fair value of equity instruments designated as measured at fair value through other comprehensive income net of tax items that will not be reclassified to profit or loss oci IFRSCurrentYTDDuration991000000JPY
Remeasurements of defined benefit plans net of tax items that will not be reclassified to profit or loss oci IFRSPrior1YTDDuration864000000JPY
Remeasurements of defined benefit plans net of tax items that will not be reclassified to profit or loss oci IFRSCurrentYTDDuration122000000JPY
Total of items that will not be reclassified to profit or loss oci IFRSPrior1YTDDuration2847000000JPY
Total of items that will not be reclassified to profit or loss oci IFRSCurrentYTDDuration1114000000JPY
Exchange differences on translation of foreign operations net of tax items that may be reclassified to profit or loss oci IFRSPrior1YTDDuration65723000000JPY
Exchange differences on translation of foreign operations net of tax items that may be reclassified to profit or loss oci IFRSCurrentYTDDuration63932000000JPY
Effective portion of cash flow hedges net of tax items that may be reclassified to profit or loss oci IFRSPrior1YTDDuration734000000JPY
Effective portion of cash flow hedges net of tax items that may be reclassified to profit or loss oci IFRSCurrentYTDDuration30000000JPY
Cost of hedging net of tax items that may be reclassified to profit or loss oci IFRSPrior1YTDDuration-341000000JPY
Cost of hedging net of tax items that may be reclassified to profit or loss oci IFRSCurrentYTDDuration-311000000JPY
Total of items that may be reclassified to profit or loss oci IFRSPrior1YTDDuration66117000000JPY
Total of items that may be reclassified to profit or loss oci IFRSCurrentYTDDuration63650000000JPY
Other comprehensive income IFRSPrior1YTDDuration68964000000JPY
Other comprehensive income IFRSCurrentYTDDuration64764000000JPY
Comprehensive income IFRSPrior1YTDDuration139144000000JPY
Comprehensive income IFRSCurrentYTDDuration144662000000JPY
Comprehensive income attributable to owners of parent IFRSPrior1YTDDuration139144000000JPY
Comprehensive income attributable to owners of parent IFRSCurrentYTDDuration144662000000JPY
Comprehensive income IFRSPrior1YTDDuration139144000000JPY
Comprehensive income IFRSCurrentYTDDuration144662000000JPY
Profit loss IFRSPrior1QuarterDuration29859000000JPY
Profit loss IFRSCurrentQuarterDuration29805000000JPY
Net change in fair value of equity instruments designated as measured at fair value through other comprehensive income net of tax items that will not be reclassified to profit or loss oci IFRSPrior1QuarterDuration93000000JPY
Net change in fair value of equity instruments designated as measured at fair value through other comprehensive income net of tax items that will not be reclassified to profit or loss oci IFRSCurrentQuarterDuration330000000JPY
Remeasurements of defined benefit plans net of tax items that will not be reclassified to profit or loss oci IFRSPrior1QuarterDuration-54000000JPY
Remeasurements of defined benefit plans net of tax items that will not be reclassified to profit or loss oci IFRSCurrentQuarterDuration-0JPY
Total of items that will not be reclassified to profit or loss oci IFRSPrior1QuarterDuration39000000JPY
Total of items that will not be reclassified to profit or loss oci IFRSCurrentQuarterDuration329000000JPY
Exchange differences on translation of foreign operations net of tax items that may be reclassified to profit or loss oci IFRSPrior1QuarterDuration-77617000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 16 of 16 passed
balance sheet identityconsolidated 2023-03-31pass
balance sheet identityconsolidated 2023-12-31pass
dei present pass
period resolution pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-12-31pass
statement vs summary · net income attributable to parentconsolidated 2022-10-01/2022-12-31pass
statement vs summary · net income attributable to parentconsolidated 2023-04-01/2023-12-31pass
statement vs summary · net income attributable to parentconsolidated 2023-10-01/2023-12-31pass
statement vs summary · operating cash flowconsolidated 2022-04-01/2022-12-31pass
statement vs summary · operating cash flowconsolidated 2023-04-01/2023-12-31pass
statement vs summary · revenueconsolidated 2022-04-01/2022-12-31pass
statement vs summary · revenueconsolidated 2022-10-01/2022-12-31pass
statement vs summary · revenueconsolidated 2023-04-01/2023-12-31pass
statement vs summary · revenueconsolidated 2023-10-01/2023-12-31pass
statement vs summary · total assetsconsolidated 2023-03-31pass
statement vs summary · total assetsconsolidated 2023-12-31pass